Redevelopment of small-cell lung cancer nine years after the start of therapy. A case report and review of the literature.
Most patients with small-cell lung cancer usually relapse within 1 to 2 years. Relapses after a 5-year disease-free interval occur extremely rarely. This report describes a patient with limited-stage small-cell lung cancer who had achieved a complete response to combination chemotherapy followed by chest irradiation but developed small-cell lung cancer 9.4 years after the beginning of therapy. Small-cell lung cancer recurred in the same side of the lung, in the mediastinal nodes, and in the liver. The pattern of development of small-cell lung cancer suggests that the patient had a relapse rather than a metachronous lung cancer. To our knowledge, this is the second-latest relapse of small-cell lung cancer in the literature.
Masuda
N
N
Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.
Fukuoka
M
M
Takada
M
M
Negoro
S
S
Matsui
K
K
Takifuji
N
N
Kudoh
S
S
Kazunobu
I
I
Nakagawa
K
K
Kusunoki
Y
Y
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001999:Bronchoscopy; D018288:Carcinoma, Small Cell / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D015376:Nimustine / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011859:Radiography; D011878:Radiotherapy / Q000592:standards; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D015376:Nimustine; D011344:Procarbazine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide